Rarest Cancer - A Review
Oncology-Rarest cancer for Review
Keywords:
Diagnoses problems, managerial challenges, rare hematologicaltumours, Worldwide Few tumours Project, uncommon malignancies, uncommon tumours in childrenAbstract
Less than six cases per 100,000 people per year, or around 22% of all cancers diagnosed worldwide, are rare malignancies. They disproportionately impact specific demographic groups. Although it is a difficult field of research, the transmission of uncommon malignancies is not extensively covered. Studying the epidemiology of rare cancers poses significant challenges and needs to be tackled more. Despite efforts, mostly in a few European countries, there have been some slight advancements in treating uncommon tumors. The causes of this obvious stagnation are multifaceted. Still, they primarily stem from logistical challenges associated with conducting clinical trials in patient populations with very low numbers, pharmaceutical companies' reluctance to invest in niche markets, and the difficulty of gathering sufficient data to develop cost-effective medications. For example, due to the lack of profitability, pharmaceutical companies may not remain willing to invest in clinical trials in patient populations with small numbers due to the financial expenses related to performing the studies could not be worth the possible rewards. Additionally, it could be challenging to acquire the data needed for the creation of affordable treatments since it might not be accessible or might be too expensive. However, it's crucial to remember that better treatments can provide significant value to patients even if those treatments have limited profitability. A key platform for establishing new international clinical trials in rare cancers is the International Rare Cancers Initiative. This review outlines the present difficulties and problems with the analysis, treatment, and study of uncommon malignancies. However, in addition to genetic changes, it is vital to look at the roles that mutation and the cell environment play in these malignancies' development, biology, and behavior. Patients with uncommon tumors struggle because clinical trials are difficult to run in this situation due to poor accrual. Individuals with not common carcinomas will only increase as more molecular subtypes of common tumours are identified. Clinical trials and research into these cancer forms must thus adjust their focus because, according to epidemiological criteria, they will eventually become uncommon tumours. This review focuses on treatments, rare cancer initiatives, problems with the treatment, tumour detection, and experimental studies.
References
Mallone S, De Angelis R, van der Zwan JM, Trama A, Siesling S, Gatta G, et al. Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. Cancer Epidemiol2013; 37: 850-6.
Mano MS, Arai RJ, Hoff PM. Rare tumors research in emerging countries. Rare Tumors 2010; 2: e49.
Bilimoria KY, Ko CY, Tomlinson JS, Stewart AK, Talamonti MS, Hynes DL, Winchester DP, Bentrem DJ. Wait times for cancer surgery in the United States: trends and predictors of delays. Annals of surgery. 2011 Apr 1;253(4):779-85.
Greenlee RT, Goodman MT, Lynch CF, Platz CE, HavenerLA, Howe HL. The occurrence of rare cancers in U.S. adults, 1995-2004. Public Health Rep 2010; 125: 28-43.
Gatta G, Capocaccia R, Trama A, Martínez-García C; RARECARE Working Group. The burden of rare cancers in Europe. AdvExp Med Biol2010; 686: 285-303.
Trama A, Mallone S, Ferretti S, Meduri F, Capocaccia R, Gatta G; RITA working group. The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. Tumori2012; 98 : 550-8.
Johnson KJ, Cullen J, Barnholtz-Sloan JS, Ostrom QT, Langer CE, Turner MC, McKean-Cowdin R, Fisher JL, Lupo PJ, Partap S, Schwartzbaum JA. Childhood Brain Tumor Epidemiology: A Brain Tumor Epidemiology Consortium Review Childhood Brain Tumor Epidemiology Review. Cancer Epidemiology, Biomarkers & Prevention. 2014 Dec 1;23(12):2716-36.
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nature reviews cancer. 2009 Mar;9(3):153-66.
Singh U, Malik MA, Goswami S, Shukla S, Kaur J. Epigenetic regulation of human retinoblastoma. Tumor Biology. 2016 Nov; 37:14427-41.
Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, Thériault BL, Prigoda-Lee NL, Spencer C, Dimaras H, Corson TW, Pang R. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. The lancet oncology. 2013 Apr 1;14(4):327-34.
Oosting, S.F.; Haddad, R.I. Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. Front. Oncol. 2019, 9, 815. [Google Scholar] [CrossRef] [PubMed][Green Version]
Gatta G, Capocaccia R, Trama A, Martínez-García C; RARECARE Working Group. The burden of rare cancers in Europe. AdvExp Med Biol2010; 686: 285-303.
Ottini L. Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer. Nat Rev Cancer 2014; 14: 643.
Guray M, Sahin AA. Benign breast diseases: classification, diagnosis, and management. The oncologist. 2006 May;11(5):435-49.
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nature reviews Gastroenterology &hepatology. 2019 Dec;16(12):713-32.
Shahid S, Teng TH, Bessarab D, Aoun S, Baxi S, Thompson SC. Factors contributing to delayed diagnosis of cancer among Aboriginal people in Australia: a qualitative study. BMJ open. 2016 Jun 1;6(6):e010909.
McCabe MS, Bhatia S, Oeffinger KC, Reaman GH, Tyne C, Wollins DS, Hudson MM. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. Journal of Clinical Oncology. 2013 Feb 2;31(5):631.
Fletcher C. Diagnostic histopathology of tumors. Edinburgh, New York: Churchill Livingstone; 1995.
Ramsay AD. Errors by locums. Histopathology departments already audit diagnostic errors. BMJ 1996; 313: 17.
Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Modern Pathology. 2003 Apr 1;16(4):376-88.
Belkacémi Y, Zouhair A, Ozsahin M, Azria D, Mirimanoff RO; Réseau des Cancers Rares (Rare Cancer Network). Prognostic factors and management of rare cancers. Cancer Radiother 2006; 10 : 323-9.
Kutikova L, Bowman L, Chang S, Long SR, Thornton DE, Crown WH. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. J Neurooncol2007; 81 : 61-5.
Youm, Y.H.; Nguyen, K.Y.; Grant, R.W.; Goldberg, E.L.; Bogodai, M.; Kim, D.; D’Agostino, D.; Planavsky, N.; Lupfer, C.; Kanneganti, T.D.; et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease. Nat. Med. 2015, 21, 263–269
Raghavan D. A structured approach to uncommon cancers: what should a clinician do? Ann Oncol2013; 24 : 2932-4.
ESMO Rare Cancer Europe. Clinical Practice Guidelines for Professionals and Guides for Patients. Available from: http://www.rarecancerseurope.org/Links/Clinical-Practice- Guidelines-for-Professionals-and-Guides-for-Patients, accessed on August 18, 2013.
Greenlee RT, Goodman MT, Lynch CF, Platz CE, Havener LA, Howe HL. The occurrence of rare cancers in U.S. adults, 1995–2004. Public Health Rep 2010; 125: 28–43.
Greenlee RT, Goodman MT, Lynch CF, Platz CE, Havener LA, Howe HL. The occurrence of rare cancers in U.S. adults, 1995-2004. Public Health Rep 2010; 125: 28-43.
Trama A, Mallone S, Ferretti S, Meduri F, Capocaccia R, Gatta G; RITA working group. The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. Tumori2012; 98 : 550-8.
Keat N, Law K, Seymour M, Welch J, Trimble T, Lascombe D, et al. International rare cancers initiative. Lancet Oncol2013;14 : 109-10.
Casali PG. Rare cancers: work in progress in Europe. Ann Oncol2014; 25 : 914.
Three-Year Progress Report for the International Rare Cancers Initiative (IRCI). Available from: http://www.eortc. org/irci/wp-content/uploads/2015/09/IRCI-3-year-report.pdf, accessed on March 28, 2013.
Chen, D.S.; Mellman, I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity 2013, 39, 1–10.
Linnemann C, van Buuren MM, Bies L, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 2015; 21: 81–85.
Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA4 blockade in melanoma. N Engl J Med 2014; 371: 2189–99.
Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablativechemoradiation preparative regimens. J ClinOncol 2008; 26: 5233–39.
Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current challenges in cancer treatment. Clinical therapeutics. 2016 Jul 1;38(7):1551-66.
Tan SB, Dear KB, Bruzzi P, Machin D. Strategy for randomized clinical trials in rare cancers. BMJ 2003; 327 : 47-9.
Gaddipati H, Liu K, Pariser A, Pazdur R. Rare cancer trial design: lessons from FDA approvals. Clin Cancer Res 2012;18: 5172-8.
Munoz J, Kurzrock R. Targeted therapy in rare cancers adopting the orphans. Nature Reviews Clinical Oncology 2012; 6: 631- 42.
Conn VS, Hafdahl AR, Porock DC, McDaniel R, Nielsen PJ. A meta-analysis of exercise interventions among people treated for cancer. Supportive Care in Cancer. 2006 Jul;14:699-712.
Natarajan PM, Umapathy VR, Murali A, Swamikannu B. Computational simulations of identified marine-derived natural bioactive compounds as potential inhibitors of oral cancer. Future Sci OA, published online on 2022. 2022;8(3):FSO782. doi: 10.2144/fsoa-2021-0148, PMID 35251696.
Umapathy VR, Natarajan PM, Swamikannu B, Moses J, Jones S, Chandran MP et al. Emerging Biosensors for Oral Cancer Detection and Diagnosis-A Review Unravelling Their Role in Past and Present Advancements in the Field of Early Diagnosis. Biosensors. 2022;12(7):498. doi: 10.3390/bios12070498, PMID 35884301.
Umapathy VR, Natarajan PM, SumathiJones C, Swamikannu B, Johnson WMS, Alagarsamy V et al. Current trends and future perspectives on dental nanomaterials – an overview of nanotechnology strategies in dentistry. J King Saud Univ Sci. 2022;34(7):102231. doi: 10.1016/j.jksus.2022.102231.
Umapathy VR, Natarajan PM, Swamikannu B. Comprehensive review on development of early diagnostics on oral cancer with a special focus on biomarkers. Appl Sci. 2022;12(10):4926. doi: 10.3390/app12104926.
Rekha U V, Mn P, S B. Review on Anticancer properties of piperine in Oral cancer: therapeutic Perspectives. Res J Pharm Technol. 2022;15(7):3338-42. doi: 10.52711/0974-360X.2022.00558.
Natarajan P, Rekha V, Murali A, Swamikannu B. Newer congeners of doxycycline – do they hold promise for periodontal therapy?. amscd. 2022;7(1):16-23. doi: 10.5114/amscd.2022.119600.
Pei J, Palanisamy CP, Alugoju P, Anthikapalli NVA, Natarajan PM, Umapathy VR et al. A comprehensive review on bio-based materials for chronic diabetic wounds. Molecules. 2023;28(2):604. doi: 10.3390/molecules28020604, PMID 36677658.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dr. Somnath Gosh, Bhuminathan .S, Lakshmi .K, M. Vinyas, Pavithraanand Ammayappan, Selva Kumar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
